SLRN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SLRN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Acelyrin is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, Acelyrin's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Acelyrin's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Acelyrin's Risk Assessment falls into.
Acelyrin (NAS:SLRN) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Acelyrin's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Shao-lee Lin | director, officer: Chief Executive Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Gil M Labrucherie | officer: Interim CFO | 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
Beth C Seidenberg | director, 10 percent owner | |
Henry O Gosebruch | director | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
Mardi Dier | officer: CFO and CBO | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Mina Kim | officer: Chief Legal & Admin. Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
Ronald Oyston | officer: Chief People Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Paul Peloso | officer: Chief Medical Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Dawn Svoronos | director | C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105 |
Daniel J. Becker | director | C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036 |
Westlake Biopartners Fund Ii, L.p. | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
Ayurmaya Capital Management Company, Lp | director, 10 percent owner, other: See Remarks | 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451 |
Sean E Harper | 10 percent owner | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Melanie Gloria | officer: Chief Operating Officer | C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301 |
Westlake Biopartners Gp Ii, Llc | 10 percent owner | 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361 |
From GuruFocus
By PRNewswire • 01-11-2024
By PRNewswire • 01-02-2024
By PRNewswire • 01-11-2024
By PRNewswire • 12-19-2023
By Business Wire • 01-08-2024
By PRNewswire • 01-06-2024
By PRNewswire • 12-28-2023
By PRNewswire • 01-09-2024
By PRNewswire • 01-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.